Tirzepatide in sleep apnea: indication and monitoring

A 52-year-old man comes to the outpatient clinic with his polysomnography in hand. The apnea-hypopnea index (AHI) is 41 events per hour, which classifies his obstructive sleep apnea as severe. His body mass index (BMI) is 38. He tried positive pressure therapy (CPAP) for two months: the mask hurt his nose, he woke up with a dry mouth and ended up putting the device away in the closet. Fasting glucose and glycated hemoglobin show prediabetes. His wife reports that he snores loudly, stops breathing at night and dozes off on the sofa after lunch. He heard about an "apnea injection" and asks whether it is for him. The scene is fictional and was written for teaching.

This text uses the case as a setting for clinical reasoning for students and health professionals. The patient's question seems simple, but it calls for several decisions: confirming that the indication exists, understanding what the studies measured, separating what the American and European agencies approved, knowing how the dose is increased and what to watch along the way. The text does not replace medical assessment, the package insert in your country or your institution's protocol. If you play the case of the day on NEXO, you will recognize the challenge: bringing together clues from different systems into a single story.

Key points

• Tirzepatide is a GIP and GLP-1 receptor agonist, given subcutaneously once a week.
• In the two SURMOUNT-OSA studies, in adults with obesity and moderate to severe apnea, it reduced the AHI far more than placebo over 52 weeks.
• The FDA approved Zepbound for moderate to severe obstructive sleep apnea in adults with obesity on December 20, 2024.
• In the European Union, the EMA did not create a separate indication for apnea: the use falls under the weight management indication, and the apnea data were included in the label.
• The dose starts at 2.5 mg per week and goes up by 2.5 mg at least every 4 weeks; for apnea, maintenance is 10 or 15 mg.
• Monitoring includes gastrointestinal symptoms, hydration and kidney function, gallbladder, pancreas, oral contraception and the risk of aspiration under anesthesia.

Why this is a reasoning setting

Obstructive sleep apnea is common and linked to cardiovascular risk. In the SURMOUNT-OSA article, Malhotra and colleagues note that more than 900 million people worldwide have the disease and that about 40 percent of them have the moderate to severe form (Malhotra and colleagues, 2024). For decades, treatment revolved around mechanical support during sleep: positive airway pressure improves the AHI and symptoms, but effectiveness depends on adherence, which varies widely (Malhotra and colleagues, 2024).

The setting is good for training because it forces you to look at the whole patient. Snoring, sleepiness, BMI and glucose are not four separate problems. The post on signs, symptoms and history shows how to organize what the patient and family report, and the post on differential diagnosis with clues helps you avoid closing the reasoning too early.

What the scene teaches

The scene trains five habits. The first is confirming that the indication applies to that patient, and not to a similar patient. The second is reading the study outcome for what it actually measures. The third is checking what each regulatory agency approved and when. The fourth is knowing the dosing schedule before prescribing or advising. The fifth is knowing what can go wrong and how to notice it early.

What is not at stake

The text does not discuss whether the patient should give up positive pressure for good. In the second SURMOUNT-OSA study, participants kept using the device, and the drug added benefit (Malhotra and colleagues, 2024). The decision about combined treatment is individual and belongs to the doctor together with the patient.

Obstructive sleep apnea and obesity: the same problem seen from two sides

Obesity and apnea go together. Excess weight narrows the upper airway and worsens collapse during sleep, and apnea in turn fragments sleep and changes metabolism. Malhotra and colleagues describe weight reduction as a strategy with the potential to treat the cause, and not just to keep the airway open at night (Malhotra and colleagues, 2024).

How severity is measured

The AHI counts apneas and hypopneas per hour of sleep (Malhotra and colleagues, 2024). In the SURMOUNT-OSA studies, it was measured by in-laboratory polysomnography at screening, at week 20 and at week 52, with centralized scoring (Malhotra and colleagues, 2024). The authors also used the sleep apnea-specific hypoxic burden (SASHB), which measures how much oxygenation falls during events (Malhotra and colleagues, 2024). The authors note that the American Academy of Sleep Medicine uses 15 events per hour as the threshold for clinical relevance (Malhotra and colleagues, 2024).

What weighs in favor of treating weight

In the patient in the scene, three facts add up: severe apnea, class 2 obesity and CPAP intolerance. He also has prediabetes, without type 2 diabetes, which matters because the SURMOUNT-OSA studies excluded people with type 1 or type 2 diabetes (Malhotra and colleagues, 2024). In other words, his profile resembles that of the people who took part in the studies, but the decision remains a clinical one.

What tirzepatide is and what it does

Tirzepatide is an agonist of the glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide 1 (GLP-1) receptors. The molecule has a fatty acid chain that binds to albumin and prolongs the half-life (Malhotra and colleagues, 2024). Singhani and colleagues report a half-life of about 5 days, which allows weekly dosing (Singhani and colleagues, 2026).

Effects that matter here

The central effect is weight loss. Malhotra and colleagues also cite improvement in blood pressure and a drop in markers of inflammation and endothelial dysfunction in earlier studies (Malhotra and colleagues, 2024). Tirzepatide delays gastric emptying, and this explains part of the gastrointestinal effects and the caution in anesthesia (US Zepbound prescribing information, revised 08/2026).

Brand names

In the United States, tirzepatide has two brands: Mounjaro, for type 2 diabetes, and Zepbound, for weight control and apnea (FDA, 2024). In the European Union, the name is Mounjaro for both purposes (EMA, 2024). Knowing this avoids confusion when the patient brings a news item, a prescription or a foreign package insert.

Who the US prescribing information indicates it for

• Reduction of excess weight and maintenance of weight loss in adults with obesity, or with overweight and at least one weight-related condition.
• Treatment of moderate to severe obstructive sleep apnea in adults with obesity.
• Always together with a lower-calorie diet and more physical activity.

Source of the list: (US Zepbound prescribing information, revised 08/2026). The prescribing information does not indicate the drug for apnea in people without obesity.

What the studies showed and what was approved

The SURMOUNT-OSA program brought together two randomized, double-blind, placebo-controlled studies at 60 centers in nine countries (Malhotra and colleagues, 2024). The first included people who could not or did not want to use positive pressure. The second included those who had already been using the device for at least 3 months and intended to continue (Malhotra and colleagues, 2024). In total, 469 participants were randomized, 234 in the first study and 235 in the second, between June 2022 and March 2024 (Malhotra and colleagues, 2024).

Who took part

The criteria called for adults with moderate to severe apnea and a BMI of 30 or more (27 or more in Japan) (Malhotra and colleagues, 2024). People with type 1 or type 2 diabetes, weight variation of more than 5 kg in the previous 3 months, planned surgery for apnea or obesity, central or mixed apnea and major craniofacial changes were left out (Malhotra and colleagues, 2024). In the second study, participants stopped the device for 7 days before each polysomnography, so that the effect of the drug could be measured without the interference of positive pressure (Malhotra and colleagues, 2024).

What changed in the AHI

In the first study, the AHI fell on average 25.3 events per hour with tirzepatide and 5.3 with placebo. In the second, it fell 29.3 with tirzepatide and 5.5 with placebo (Malhotra and colleagues, 2024). An important share of the treated participants, up to 50.2 percent, reached an AHI compatible with remission or with mild disease without symptoms (Malhotra and colleagues, 2024). Hypoxic burden, systolic pressure, C-reactive protein and patient-reported outcomes also improved (Malhotra and colleagues, 2024). In the label, the average weight loss in the two studies was 17.7 percent and 19.6 percent with tirzepatide (US Zepbound label, revised in 08/2026).

Aspect	Study 1 (without positive pressure)	Study 2 (with positive pressure)
Randomized participants	234	235
Average AHI drop with tirzepatide	25.3 events per hour	29.3 events per hour
Average AHI drop with placebo	5.3 events per hour	5.5 events per hour
Dose	Maximum tolerated, 10 or 15 mg per week	Maximum tolerated, 10 or 15 mg per week
Duration	52 weeks	52 weeks

Table sources: (Malhotra and colleagues, 2024) and (US Zepbound label, revised in 08/2026). The numbers are study averages and not predictions for a patient.

Does weight explain the effect?

Largely, yes. Lin and colleagues reanalyzed the data and saw that those who lost 10 or 15 percent of their weight by week 20 had a greater AHI drop, more remission and lower hypoxic burden at the end of the study (Lin and colleagues, 2026). Falcon and colleagues showed that the improvement appeared in several subgroups defined by baseline characteristics (Falcon and colleagues, 2026). Kanu and colleagues showed improvement in reported symptoms also in those who started with more intense symptoms (Kanu and colleagues, 2026).

And cardiometabolic risk?

In a secondary analysis published in 2026, Malhotra and colleagues described improvement in lipids and in insulin resistance measured by HOMA-IR (Malhotra and colleagues, 2026). The mediation analysis suggested that the improvement in AHI and hypoxic burden explains part of the drop in C-reactive protein, HOMA-IR and triglycerides, but not in blood pressure (Malhotra and colleagues, 2026). In another population, that of heart failure with preserved ejection fraction and obesity, an analysis of the SUMMIT study suggested less circulatory congestion with tirzepatide (Borlaug and colleagues, 2025). These are results that help understand the mechanism, but they do not change the label indication.

The limits

The authors themselves point out that apnea accompanies the patient for years, while the studies lasted 52 weeks (Malhotra and colleagues, 2024). It is not known, from the study data, what happens to the AHI when the drug is stopped. There was also no direct comparison with CPAP as the only treatment.

Regulatory status: FDA and EMA

The regulatory status changes from one place to another, and the patient who reads international news may arrive with an expectation that does not apply in their country. So it is worth checking the primary sources, with dates.

United States. On December 20, 2024, the FDA approved Zepbound for moderate to severe obstructive apnea in adults with obesity, together with a lower-calorie diet and more physical activity; the agency described it as the first drug for this condition (FDA, 2024). The label in force on the date of this text was revised in 08/2026 and keeps this indication (US Zepbound label, revised in 08/2026).

European Union. On December 13, 2024, the EMA completed the assessment of the application to extend the Mounjaro indication to the treatment of obstructive sleep apnea in adults with obesity (EMA, 2024). The Committee for Medicinal Products for Human Use (CHMP) did not approve a separate indication, because it considered that this use is already covered by the weight management indication; the sleep apnea study results were added to section 5.1 of the summary of product characteristics (EMA, 2024). In practice, an adult with obesity and sleep apnea can receive the drug under the weight indication, according to the medical assessment.

Other countries. Outside the United States and the European Union, the indication depends on the local agency. The right question for the patient in the scene is: what does the label approved in my country say? This text does not cover national agencies outside those two.

How the dose starts and how it is adjusted

The tirzepatide dosing schedule is stepped up to reduce gastrointestinal effects. The values below come from the American label and the study protocol.

Step-up

• Start: 2.5 mg subcutaneously once a week for 4 weeks.
• Then increases of 2.5 mg after at least 4 weeks at the current dose.
• For sleep apnea, the maintenance dose is 10 mg or 15 mg once a week.
• The maximum dose for all indications is 15 mg per week.
• Missed dose: take it as soon as possible, within 4 days (96 hours); after that, skip it and continue on the usual day.

Source of the list: (American Zepbound label, revised 08/2026). In the SURMOUNT-OSA studies, the dose went up 2.5 mg every 4 weeks to the maximum tolerated dose, 10 or 15 mg, reached by week 20 (Malhotra et al., 2024).

When the dose is not tolerated

Singhani et al. suggest, in the face of persistent nausea, going back to the previous dose for 4 weeks before trying to increase again (Singhani et al., 2026). The same review recommends smaller, low-fat meals, sitting or standing after eating and avoiding eating in the 3 hours before going to bed (Singhani et al., 2026). Stepping up slowly, at most once a month, is the most cited measure for nausea at the start (Singhani et al., 2026).

Before the first dose

The label contraindicates the drug in people with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2, and in those who have already had a serious hypersensitivity reaction to tirzepatide (American Zepbound label, revised 08/2026). The boxed warning on the label covers the risk of thyroid C-cell tumors, seen in rodents (American Zepbound label, revised 08/2026). That is why family history comes up at the first visit.

What to monitor

Follow-up has two goals: to see whether the treatment works and to notice early what can go wrong. The table organizes the main points.

What to watch	Why	How
Nausea, vomiting, diarrhea	These are the most common effects and can be serious	Ask at every visit; step up slowly
Hydration and kidney function	Fluid loss can cause acute kidney injury	Advise intake; creatinine if there is fluid loss
Severe abdominal pain	May indicate pancreatitis or gallbladder disease	Stop and investigate if suspected
Blood glucose	Hypoglycemia with a sulfonylurea or insulin	Review these drugs when starting
Oral contraception	Slow gastric emptying can reduce absorption	Non-oral or barrier method for 4 weeks after starting and after each increase
Surgery and sedation	Retained gastric contents and risk of aspiration	Inform the anesthesia team

Sources of the table: (American Zepbound label, revised 08/2026), (Kindel et al., 2025) and (Singhani et al., 2026).

Digestive system

The label lists serious gastrointestinal reactions, acute kidney injury from volume loss, gallbladder disease and pancreatitis among the warnings (American Zepbound label, revised 08/2026). In the SURMOUNT-OSA article, two participants in the treated group had pancreatitis (Malhotra et al., 2024). In the face of severe and persistent abdominal pain, the label advises stopping the drug and investigating (American Zepbound label, revised 08/2026).

Blood glucose and retina

The patient in the scene has prediabetes and does not take diabetes medication. People who take sulfonylureas or insulin are at higher risk of hypoglycemia: in a study from the label, hypoglycemia occurred in 10.3 percent of those using sulfonylureas, versus 2.1 percent of those not using them (US Zepbound label, revised 08/2026). In people with diabetes and retinopathy, the label calls for monitoring of progression (US Zepbound label, revised 08/2026).

Contraception and other oral medicines

Because tirzepatide delays gastric emptying, the label advises switching from oral contraception to a non-oral method, or adding a barrier method, for 4 weeks after starting and for 4 weeks after each dose increase (US Zepbound label, revised 08/2026). The label also calls for attention to oral medicines with a narrow therapeutic margin, such as warfarin (US Zepbound label, revised 08/2026).

Anesthesia and endoscopy

The label records rare reports of pulmonary aspiration during general anesthesia or deep sedation in users of this type of medicine (US Zepbound label, revised 08/2026). Guidance from several societies gathered by Kindel and colleagues assesses the risk before the procedure: recent dose escalation, a higher dose, weekly use, gastrointestinal symptoms and conditions that already delay emptying increase the risk (Kindel and colleagues, 2025). Without these factors, the medicine can be maintained; when the risk is higher, options include a liquid diet for at least 24 hours beforehand, gastric ultrasound on the day, if available, and rapid sequence induction (Kindel and colleagues, 2025). If the decision is to suspend it, the guidance for weekly medicines is to stop one week before (Kindel and colleagues, 2025).

Age and lean mass

The patient in the scene is 52 years old, but the question comes up in older adults. Alfaris and colleagues, in an analysis of people aged 65 or older in the SURMOUNT and SUMMIT studies, saw weight loss similar to that of younger people and a drop in both fat and lean mass (Alfaris and colleagues, 2026). In those who already have little muscle mass, weight loss calls for attention to protein intake and physical activity (Alfaris and colleagues, 2026).

The apnea response

Apnea control is not measured by the scale alone. In the studies, the AHI was reassessed by polysomnography at week 20 and at week 52 (Malhotra and colleagues, 2024). Lin and colleagues suggest that early weight loss helps predict who will respond better (Lin and colleagues, 2026). If symptoms persist, the decision about a new polysomnography and about resuming positive pressure is medical.

How NEXO helps train this reasoning

In NEXO, you try the diagnosis by searching for the ICD-10 code and receive proximity feedback in five levels, which shows whether the guess landed on the exact code, the same category, the same group, the same chapter or a different chapter. This format fits the theme of this text: sleep apnea, obesity and prediabetes sit in different chapters of the classification, but appear in the same patient. The post about ICD-10 shows how to find the right code.

To use the case of the day as training, try three habits. Before the first guess, ask which clues belong to the same mechanism. With each clue, ask whether it changes management or only confirms what you already thought. After the result, note the clue you failed to connect to the others.

Three exercises with cases

Connect the systems. In each case with obesity, say which respiratory or sleep complaint could have the same origin.

Check the indication. Faced with a new medicine, say which agency approved it, for whom and on what date.

Anticipate the risk. List three adverse effects you would monitor in the first 8 weeks.

The post about diagnostic uncertainty discusses how to decide when the data do not yet add up, the post about case-based learning in clinical practice shows how cases help fix these habits, and the post about clinical deterioration on the ward reminds us that persistent vomiting and dehydration are also warning signs.

The limits on using the game are described on the Economy page of NEXO. If you research the teaching of clinical reasoning, the page for Researcher explains how to get in touch. Professionals who write or review cases find information on Curator and on Creators, and institutions can learn about the proposal on the partnerships page.

Frequently asked questions

Does tirzepatide replace CPAP?

Not necessarily. In the second SURMOUNT-OSA study, participants stayed on the device and the drug added benefit (Malhotra et al., 2024). The decision is individual.

Does it work for people with apnea but without obesity?

Not according to the US label, which restricts the indication to adults with obesity (US Zepbound label, revised in 08/2026).

Is it approved for apnea in Europe?

Not as a separate indication. The EMA considered the use covered by the weight-control indication and added the apnea data to the label (EMA, 2024).

How long does it take to reach the maintenance dose?

With increases every 4 weeks, the 10 mg dose is reached at week 12 and the 15 mg dose at week 20, if tolerated (US Zepbound label, revised in 08/2026), (Malhotra et al., 2024).

Do I need to stop it before surgery?

Not always. Guidance from several societies weighs the risk of delayed gastric emptying; the anesthesia team decides (Kindel et al., 2025).

Final checklist

• I confirmed moderate to severe apnea by polysomnography and obesity by BMI.
• I checked the label approved in the country and the date of the regulatory decision.
• I asked about medullary thyroid carcinoma and multiple endocrine neoplasia type 2 in the family.
• I reviewed medicines that cause hypoglycemia and oral contraceptives.
• I explained the step-up from 2.5 mg every 4 weeks and what to do about a missed dose.
• I gave guidance on nausea, hydration and abdominal pain that requires seeking care.
• I agreed to notify the anesthesia team before any surgery or endoscopy.
• I planned to reassess symptoms, weight and, if indicated, a new polysomnography.

Want to practice reasoning with progressive clues? Play the case of the day.

References

1. Alfaris N, Kushner RF, Li J, et al. Tirzepatide for Obesity in Adults ≥ 65 Years: A Post Hoc Analysis of the SURMOUNT and SUMMIT Clinical Trials. Diabetes Obes Metab. 2026. PMID 42303274.
2. Borlaug BA, Zile MR, Kramer CM, et al. Effects of tirzepatide on circulatory overload and end-organ damage in heart failure with preserved ejection fraction and obesity: a secondary analysis of the SUMMIT trial. Nat Med. 2025. PMID 39551891.
3. Eli Lilly and Company. ZEPBOUND® (tirzepatide) Injection, for subcutaneous use. Prescribing Information. Revised in 08/2026. Accessed on 24/10/2026. Official source.
4. European Medicines Agency. Outcome of assessment on use of Mounjaro in treatment of obstructive sleep apnoea. EMA/576853/2024. 13/12/2024. Official source.
5. Falcon B, Xie CC, Redline S, et al. Association of tirzepatide with changes in OSA-related measures based on baseline characteristics - post hoc analyses of SURMOUNT-OSA. J Clin Sleep Med. 2026. PMID 42675225.
6. Kanu C, Shinde S, Falcon B, et al. Changes in patient-reported outcomes and objective assessments based on baseline symptom severity in SURMOUNT-OSA: post-hoc analyses. Sleep. 2026. PMID 42412744.
7. Kindel TL, Wang AY, Wadhwa A, et al. Multi-society clinical practice guidance for the safe use of glucagon-like peptide-1 receptor agonists in the perioperative period. Surg Endosc. 2025. PMID 39370500.
8. Lin YN, Sun XW, Dai SJ, et al. Association between early body weight reduction and treatment outcomes in participants with obstructive sleep apnoea and obesity: a post hoc analysis of SURMOUNT-OSA trials. EClinicalMedicine. 2026. PMID 42774617.
9. Malhotra A, Grunstein RR, Fietze I, et al. Tirzepatide for the Treatment of Obstructive Sleep Apnea and Obesity. N Engl J Med. 2024. PMID 38912654.
10. Malhotra A, Grunstein R, Azarbarzin A, et al. Tirzepatide on obstructive sleep apnea-related cardiometabolic risk: secondary outcomes of the SURMOUNT-OSA randomized trial. Nat Med. 2026. PMID 41540105.
11. Singhani V, Ehsan M, Valencia S, et al. Gastrointestinal adverse effects of GLP-1 receptor agonists and dual GIP/GLP-1 receptor agonists: A narrative expert review of approved therapies, oral formulations, and pipeline agents. Nutr Clin Pract. 2026. PMID 42808923.
12. U.S. Food and Drug Administration. FDA Approves First Medication for Obstructive Sleep Apnea. 20/12/2024. Official source.